aTyr Pharma Investors May Lead Class‑Action Lawsuit, Says Faruqi & Faruqi LLP

Law firm Faruqi & Faruqi, LLP (FF) announced it is investigating possible securities‑law violations by aTyr Pharma, Inc. (NASDAQ: ATYR) and is seeking investors who purchased the company’s securities between January 16, 2025 and September 12, 2025, to consider serving as lead plaintiff in a class action.  The complaint alleges that aTyr and its executives made “overwhelmingly positive” statements about its experimental drug efzofitimod — particularly its ability to enable complete steroid withdrawal for patients — while concurrently failing to disclose material adverse facts.  According to the lawsuit summary, in the EFZO‑FIT trial efzofitimod failed to meaningfully reduce the mean daily oral corticosteroid dose at week 48 (2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo). Only 52.6 % of treated patients achieved complete steroid withdrawal, compared with 40.2 % on placebo.  Following the data release, aTyr’s share price plunged by approximately 83.25 %, falling from a close of US $6.03 on September 12 to US $1.01 by market close on September 15.  FF reminds investors that the deadline to move to be lead plaintiff is December 8, 2025 and encourages anyone with relevant information — including former employees, whistleblowers or shareholders — to contact the firm. #aTyrPharma #SecuritiesLitigation #ClassAction #InvestorAlert #SlimScan #GrowthStocks #CANSLIM